C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study

Table 3 Comparison of trough serum infliximab (IFX), C-reactive protein (CRP) levels, partial Mayo Score and subscores in subgroups of patients with ulcerative colitis at week 14 following the initiation of IFX infusion

Variable	IFX responders (n = 29)	IFX partial-responders (n = 24)	IFX non-responders (n = 10^a)	P₁ Value	P₂ Value
Trough IFX (μg/mL)	12.4 [3.2–22.4]	9.1 [3.9–13.9]	17.6 [4.9–28.8]	0.8851	0.7274
CRP (mg/dL)	0.04 [0.01–0.07]	0.56 [0.27–0.96]	0.11 [0.02–0.50]	0.0009	0.01911
Partial Mayo Score (0–9)	0 [0–1]	4 [4–6]	6.5 [5.5–7.3]	<0.0001	<0.0001
Stool frequency (0–3)	0 [0–0]	2 [2–3]	3 [2–3]	<0.0001	<0.0001
Rectal bleeding (0–3)	0 [0–0]	1 [1–2]	2 [2–2.5]	<0.0001	<0.0001
PGA (0–3)	0 [0–0]	1 [1–1]	2 [1.5-2]	<0.0001	<0.0001

Data are presented as the median [interquartile range] values and compared by Wilcoxon-Mann–Whitney test. P₁, responder vs partial-responder; P₂, responder vs non-responder
PGA Physician’s global assessment
^a Only 10 of 19 patients were available for evaluation at week 14 visit, the other 9 had withdrawn due to worsened UC

ISSN: 1471-230X